Botulinum toxin type a for the prophylactic treatment of primary headache disorders

Research output: Chapter in Book/Report/Conference proceedingChapter

Abstract

Introduction Migraine is a chronic neurovascular disorder that afflicts 8-15 per cent of the world’s population and is the most common primary headache disorder in clinical practice. In the United States there are an estimated 28 million migraine sufferers, with women being affected three times as often as men1. It is characterized by severe headaches and is often associated with nausea, vomiting, heightened sensitivity to sound and light, and focal (paresthesias, visual scintillations) and global (impaired concentration) neurological dysfunction. Migraine is considered to be one of the top 20 causes of disability due to chronic diseases, and severe migraine has been judged by the World Health Organization to be as disabling as quadriplegia, psychosis, and dementia2. Most sufferers are in their most socially active and productive years (25-55)1. Not only is migraine painful and disabling for the sufferer, but it exerts a significant economic burden on society. It causes 112 million bedridden days each year and costs $14 billion in reduced productivity and missed workdays3. The economic burden of migraine is comparable with that of diabetes4and higher than that of asthma5. Even among migraineurs who consult a physician, many are not satisfied with their therapy and report that prescribed medications are not always optimal. Triptan medications, the most effective acute therapy for migraine attacks, are only effective in improving the pain and associated migraine symptoms, such as photophobia and nausea, in up to two thirds of patients

Original languageEnglish (US)
Title of host publicationClinical uses of Botulinum Toxins
PublisherCambridge University Press
Pages229-242
Number of pages14
Volume9780521833042
ISBN (Print)9780511544842, 0521833043, 9780521833042
DOIs
StatePublished - Jan 1 2007

Fingerprint

Primary Headache Disorders
Botulinum Toxins
Migraine Disorders
Therapeutics
Nausea
Economics
Tryptamines
Photophobia
Quadriplegia
Paresthesia
Psychotic Disorders
Vomiting
Headache
Chronic Disease
Physicians
Light
Costs and Cost Analysis
Pain

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Dodick, D. W. (2007). Botulinum toxin type a for the prophylactic treatment of primary headache disorders. In Clinical uses of Botulinum Toxins (Vol. 9780521833042, pp. 229-242). Cambridge University Press. https://doi.org/10.1017/CBO9780511544842.011

Botulinum toxin type a for the prophylactic treatment of primary headache disorders. / Dodick, David William.

Clinical uses of Botulinum Toxins. Vol. 9780521833042 Cambridge University Press, 2007. p. 229-242.

Research output: Chapter in Book/Report/Conference proceedingChapter

Dodick, DW 2007, Botulinum toxin type a for the prophylactic treatment of primary headache disorders. in Clinical uses of Botulinum Toxins. vol. 9780521833042, Cambridge University Press, pp. 229-242. https://doi.org/10.1017/CBO9780511544842.011
Dodick DW. Botulinum toxin type a for the prophylactic treatment of primary headache disorders. In Clinical uses of Botulinum Toxins. Vol. 9780521833042. Cambridge University Press. 2007. p. 229-242 https://doi.org/10.1017/CBO9780511544842.011
Dodick, David William. / Botulinum toxin type a for the prophylactic treatment of primary headache disorders. Clinical uses of Botulinum Toxins. Vol. 9780521833042 Cambridge University Press, 2007. pp. 229-242
@inbook{08a492950e5c46e1af7727a1a8eca47f,
title = "Botulinum toxin type a for the prophylactic treatment of primary headache disorders",
abstract = "Introduction Migraine is a chronic neurovascular disorder that afflicts 8-15 per cent of the world’s population and is the most common primary headache disorder in clinical practice. In the United States there are an estimated 28 million migraine sufferers, with women being affected three times as often as men1. It is characterized by severe headaches and is often associated with nausea, vomiting, heightened sensitivity to sound and light, and focal (paresthesias, visual scintillations) and global (impaired concentration) neurological dysfunction. Migraine is considered to be one of the top 20 causes of disability due to chronic diseases, and severe migraine has been judged by the World Health Organization to be as disabling as quadriplegia, psychosis, and dementia2. Most sufferers are in their most socially active and productive years (25-55)1. Not only is migraine painful and disabling for the sufferer, but it exerts a significant economic burden on society. It causes 112 million bedridden days each year and costs $14 billion in reduced productivity and missed workdays3. The economic burden of migraine is comparable with that of diabetes4and higher than that of asthma5. Even among migraineurs who consult a physician, many are not satisfied with their therapy and report that prescribed medications are not always optimal. Triptan medications, the most effective acute therapy for migraine attacks, are only effective in improving the pain and associated migraine symptoms, such as photophobia and nausea, in up to two thirds of patients",
author = "Dodick, {David William}",
year = "2007",
month = "1",
day = "1",
doi = "10.1017/CBO9780511544842.011",
language = "English (US)",
isbn = "9780511544842",
volume = "9780521833042",
pages = "229--242",
booktitle = "Clinical uses of Botulinum Toxins",
publisher = "Cambridge University Press",

}

TY - CHAP

T1 - Botulinum toxin type a for the prophylactic treatment of primary headache disorders

AU - Dodick, David William

PY - 2007/1/1

Y1 - 2007/1/1

N2 - Introduction Migraine is a chronic neurovascular disorder that afflicts 8-15 per cent of the world’s population and is the most common primary headache disorder in clinical practice. In the United States there are an estimated 28 million migraine sufferers, with women being affected three times as often as men1. It is characterized by severe headaches and is often associated with nausea, vomiting, heightened sensitivity to sound and light, and focal (paresthesias, visual scintillations) and global (impaired concentration) neurological dysfunction. Migraine is considered to be one of the top 20 causes of disability due to chronic diseases, and severe migraine has been judged by the World Health Organization to be as disabling as quadriplegia, psychosis, and dementia2. Most sufferers are in their most socially active and productive years (25-55)1. Not only is migraine painful and disabling for the sufferer, but it exerts a significant economic burden on society. It causes 112 million bedridden days each year and costs $14 billion in reduced productivity and missed workdays3. The economic burden of migraine is comparable with that of diabetes4and higher than that of asthma5. Even among migraineurs who consult a physician, many are not satisfied with their therapy and report that prescribed medications are not always optimal. Triptan medications, the most effective acute therapy for migraine attacks, are only effective in improving the pain and associated migraine symptoms, such as photophobia and nausea, in up to two thirds of patients

AB - Introduction Migraine is a chronic neurovascular disorder that afflicts 8-15 per cent of the world’s population and is the most common primary headache disorder in clinical practice. In the United States there are an estimated 28 million migraine sufferers, with women being affected three times as often as men1. It is characterized by severe headaches and is often associated with nausea, vomiting, heightened sensitivity to sound and light, and focal (paresthesias, visual scintillations) and global (impaired concentration) neurological dysfunction. Migraine is considered to be one of the top 20 causes of disability due to chronic diseases, and severe migraine has been judged by the World Health Organization to be as disabling as quadriplegia, psychosis, and dementia2. Most sufferers are in their most socially active and productive years (25-55)1. Not only is migraine painful and disabling for the sufferer, but it exerts a significant economic burden on society. It causes 112 million bedridden days each year and costs $14 billion in reduced productivity and missed workdays3. The economic burden of migraine is comparable with that of diabetes4and higher than that of asthma5. Even among migraineurs who consult a physician, many are not satisfied with their therapy and report that prescribed medications are not always optimal. Triptan medications, the most effective acute therapy for migraine attacks, are only effective in improving the pain and associated migraine symptoms, such as photophobia and nausea, in up to two thirds of patients

UR - http://www.scopus.com/inward/record.url?scp=84926982953&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84926982953&partnerID=8YFLogxK

U2 - 10.1017/CBO9780511544842.011

DO - 10.1017/CBO9780511544842.011

M3 - Chapter

AN - SCOPUS:84926982953

SN - 9780511544842

SN - 0521833043

SN - 9780521833042

VL - 9780521833042

SP - 229

EP - 242

BT - Clinical uses of Botulinum Toxins

PB - Cambridge University Press

ER -